Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protocol T: Little Difference In Eylea, Lucentis Efficacy At Two Years

This article was originally published in Scrip

Executive Summary

The 660-patient Protocol T clinical trial, which was designed to compare the efficacy and safety of three vascular endothelial growth factor (VEGF) inhibitors used to treat diabetic macular edema (DME), show that the efficacy gap between Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept) and Genentech's Lucentis (ranibizumab) at one year narrowed with no major difference in the second year.

Advertisement

Related Content

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Advertisement
UsernamePublicRestriction

Register

SC064618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel